96 related articles for article (PubMed ID: 17340591)
1. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019.
Lee WR; Bae K; Lawton C; Gillin M; Morton G; Firat S; Baikadi M; Kuettel M; Greven K; Sandler H
Cancer; 2007 Apr; 109(8):1506-12. PubMed ID: 17340591
[TBL] [Abstract][Full Text] [Related]
2. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809.
Hurwitz MD; Halabi S; Archer L; McGinnis LS; Kuettel MR; DiBiase SJ; Small EJ
Cancer; 2011 Dec; 117(24):5579-88. PubMed ID: 22535500
[TBL] [Abstract][Full Text] [Related]
3. Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.
Michalski JM; Winter KA; Prestidge BR; Sanda MG; Amin M; Bice WS; Gay HA; Ibbott GS; Crook JM; Catton CN; Raben A; Bosch W; Beyer DC; Frank SJ; Papagikos MA; Rosenthal SA; Barthold HJ; Roach M; Moughan J; Sandler HM
J Clin Oncol; 2023 Aug; 41(24):4035-4044. PubMed ID: 37315297
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321.
Hsu IC; Bae K; Shinohara K; Pouliot J; Purdy J; Ibbott G; Speight J; Vigneault E; Ivker R; Sandler H
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):751-8. PubMed ID: 20207506
[TBL] [Abstract][Full Text] [Related]
5. High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients.
Tselis N; Tunn UW; Chatzikonstantinou G; Milickovic N; Baltas D; Ratka M; Zamboglou N
Radiat Oncol; 2013 May; 8():115. PubMed ID: 23656899
[TBL] [Abstract][Full Text] [Related]
6. Treatment of low-risk prostate cancer: a retrospective study with 477 patients comparing external beam radiotherapy and I-125 seeds brachytherapy in terms of biochemical control and late side effects.
Moll M; Paschen C; Zaharie A; Berndl F; Goldner G
Strahlenther Onkol; 2021 Feb; 197(2):118-123. PubMed ID: 32642874
[TBL] [Abstract][Full Text] [Related]
7. Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer.
Moll M; Renner A; Kirisits C; Paschen C; Zaharie A; Goldner G
Strahlenther Onkol; 2021 Nov; 197(11):986-992. PubMed ID: 34351453
[TBL] [Abstract][Full Text] [Related]
8. [Combination of internal and external beam radiotherapy].
Giraudet AL
Cancer Radiother; 2023 Dec; 27(8):754-758. PubMed ID: 37953187
[TBL] [Abstract][Full Text] [Related]
9. Paediatric radiotherapy in the United Kingdom: an evolving subspecialty and a paradigm for integrated teamworking in oncology.
Colori A; Ackwerh R; Chang YC; Cody K; Dunlea C; Gains JE; Gaunt T; Gillies CMS; Hardy C; Lalli N; Lim PS; Soto C; Gaze MN
Br J Radiol; 2024 Jan; 97(1153):21-30. PubMed ID: 38263828
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy side effects: integrating a survivorship clinical lens to better serve patients.
Dilalla V; Chaput G; Williams T; Sultanem K
Curr Oncol; 2020 Apr; 27(2):107-112. PubMed ID: 32489253
[TBL] [Abstract][Full Text] [Related]
11. Bone pain from spinal metastases: Iodine-125 brachytherapy.
Shao H; Teng L; Dai J; Zhang W; Lin S; Zhao L; Zou H
BMJ Support Palliat Care; 2021 Nov; ():. PubMed ID: 34732474
[TBL] [Abstract][Full Text] [Related]
12. High-Risk Localized Prostate Cancer: How Important Is the Addition of Brachytherapy to External-Beam Radiotherapy?
Gomez-Iturriaga A; Crook J
J Clin Oncol; 2018 Sep; ():JCO1800704. PubMed ID: 30212300
[No Abstract] [Full Text] [Related]
13. Editorial Comment to Nonmetastatic castration-resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy.
Hirayama Y; Iguchi T
IJU Case Rep; 2021 Jul; 4(4):230-231. PubMed ID: 34258535
[No Abstract] [Full Text] [Related]
14. Correction to: Comparison of outcomes in high‑risk prostate cancer patients treated with low‑/high‑dose‑rate brachytherapy plus external beam radiotherapy.
Imai Y; Urabe F; Iwatani K; Nakazono M; Tashiro K; Honda M; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
Int J Clin Oncol; 2023 Dec; 28(12):1697. PubMed ID: 37812316
[No Abstract] [Full Text] [Related]
15. Future directions of in vivo dosimetry for external beam radiotherapy and brachytherapy.
Verhaegen F; Fonseca GP; Johansen JG; Beaulieu L; Beddar S; Greer P; Jornet N; Kertzscher G; McCurdy B; Smith RL; Mijnheer B; Olaciregui-Ruiz I; Tanderup K
Phys Imaging Radiat Oncol; 2020 Oct; 16():18-19. PubMed ID: 33458338
[No Abstract] [Full Text] [Related]
16. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.
Hoskin PJ; Rojas AM; Bownes PJ; Lowe GJ; Ostler PJ; Bryant L
Radiother Oncol; 2012 May; 103(2):217-22. PubMed ID: 22341794
[TBL] [Abstract][Full Text] [Related]
17. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
Grimm P; Billiet I; Bostwick D; Dicker AP; Frank S; Immerzeel J; Keyes M; Kupelian P; Lee WR; Machtens S; Mayadev J; Moran BJ; Merrick G; Millar J; Roach M; Stock R; Shinohara K; Scholz M; Weber E; Zietman A; Zelefsky M; Wong J; Wentworth S; Vera R; Langley S
BJU Int; 2012 Feb; 109 Suppl 1():22-9. PubMed ID: 22239226
[TBL] [Abstract][Full Text] [Related]
19. Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).
Crook J; Rodgers JP; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Murtha AD; Vigneault E; Helou J; Michalski JM; Roach M; Beyer D; Jani AB; Horwitz EM; Raben A; Pugh S; Sandler H
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1115-1122. PubMed ID: 34740768
[TBL] [Abstract][Full Text] [Related]
20. A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate.
Fischer-Valuck BW; Gay HA; Patel S; Baumann BC; Michalski JM
Front Oncol; 2019; 9():1378. PubMed ID: 31921640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
